<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02180711</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-LY-003</org_study_id>
    <nct_id>NCT02180711</nct_id>
  </id_info>
  <brief_title>Study of Acalabrutinib Alone or in Combination With Rituximab in Indolent B-cell Non-Hodgkin Lymphoma</brief_title>
  <official_title>An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination With Rituximab in Subjects With Indolent B Cell Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acerta Pharma BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Acerta Pharma, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Acerta Pharma BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the safety profile of acalabrutinib alone or in combination with rituximab in
      subjects with Indolent B-cell Non-Hodgkin Lymphoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination with Rituximab in
      Subjects with Indolent B cell Non-Hodgkin Lymphoma - Marginal Zone Lymphoma
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (AEs)</measure>
    <time_frame>From first dose of study drug to within 30 days of last dose of study drug</time_frame>
    <description>Number of participants who had experienced at least one treatment emergent AE</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Follicular Lymphoma (FL)</condition>
  <arm_group>
    <arm_group_label>acalabrutinib Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>acalabrutinib Regimen 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acalabrutinib Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>acalabrutinib Regimen 2 + rituximab for relapsed, refractory, or treatment naive subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acalabrutinib</intervention_name>
    <arm_group_label>acalabrutinib Regimen 1</arm_group_label>
    <arm_group_label>acalabrutinib Regimen 2</arm_group_label>
    <other_name>ACP-196</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab (IV)</intervention_name>
    <arm_group_label>acalabrutinib Regimen 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ≥ 18 years of age.

          -  Part 1: A confirmed diagnosis of FL Grade 1, 2, or 3a, which has relapsed after, or
             been refractory to ≥ 1 prior therapy for FL, or subjects who have not previously
             received systemic anticancer therapy for FL., and which requires treatment.

        Part 2:Histologically confirmed MZL including splenic, nodal, and extranodal sub- types

          1. Subjects with splenic MZL must have an additional measurable lesion, nodal or
             extranodal, as described in inclusion criterion #4;

          2. Subjects with gastric mucosa-associated lymphoid tissue (MALT) lymphoma must be
             Helicobacter pylori (HP)-negative

               -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.

               -  Agreement to use contraception during the study and for 30 days after the last
                  dose of study drugs if sexually active and able to bear or beget children.

        Exclusion Criteria:

          -  •A life-threatening illness, medical condition or organ system dysfunction which, in
             the investigator's opinion, could compromise the subject's safety, interfere with the
             absorption or metabolism of acalabrutinib, or put the study outcomes at undue risk

          -  Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias,
             congestive heart failure, or myocardial infarction within 6 months of screening, or
             any Class 3 or 4 cardiac disease as defined by the New York Heart Association
             Functional Classification, or Qtc &gt;480 msec

          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function, or
             resection of the stomach or small bowel, gastric bypass, symptomatic inflammatory
             bowel disease, or partial or complete bowel obstruction.

          -  Breast feeding or pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorothy Nguyen, MD.</last_name>
    <role>Study Director</role>
    <affiliation>Acerta Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Call center</last_name>
    <phone>1-888-292-9613</phone>
    <email>acertamc@dlss.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lacolle Peters</last_name>
      <phone>626-218-4632</phone>
      <email>lapeters@coh.org</email>
    </contact>
    <investigator>
      <last_name>Robert Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Burge Tonya</last_name>
      <phone>312-942-3309</phone>
      <email>tonya_m_burge@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Parameswaran Venugopal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Madden</last_name>
      <phone>773-834-4574</phone>
      <email>jmadden@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Sonali Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Haycraft</last_name>
      <email>dana.haycraft@nortonhealthcare.org</email>
    </contact>
    <contact_backup>
      <last_name>Heather Woolridge</last_name>
      <email>heather.woolridge@nortonhealthcare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Don Stevens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan, Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Alliance</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Kats</last_name>
      <email>ckats@researchcra.com</email>
    </contact>
    <contact_backup>
      <last_name>Judith Lovecchio</last_name>
      <email>jlovecchio@researchcra.com</email>
    </contact_backup>
    <investigator>
      <last_name>Morton Coleman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Jenkins, RN, BSN</last_name>
      <phone>614-366-0855</phone>
      <email>cynthia.jenkins@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Beth Christian, MD</last_name>
      <email>Beth.Christian@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Beth Christian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Frye</last_name>
      <email>anna.frye@hci.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lindsay Carpenter</last_name>
      <email>lindsay.carpenter@hci.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Deborah Stephens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2014</study_first_submitted>
  <study_first_submitted_qc>July 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2014</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bruton tyrosine kinase inhibitor</keyword>
  <keyword>Btk</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>FL</keyword>
  <keyword>acalabrutinib</keyword>
  <keyword>ACP-196</keyword>
  <keyword>MZL</keyword>
  <keyword>Marginal Zone Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

